2024 - A New Paradigm in the Detection of Amyloid Pathology: The Emergence of Highly Accurate Blood Tests

Webinar Preview
The availability of disease-modifying treatments (DMTs) for early symptomatic Alzheimer’s disease (AD) has vastly increased the need for clinical AD biomarker testing. Blood biomarkers help in determining whether cognitive impairment is caused by AD. Biomarker evidence of amyloid pathology is essential prior to initiation of DMTs.
This webinar will review the types of blood biomarker tests for AD that are clinically available: amyloid positron emission tomography (PET) and AD blood tests. The Imaging Dementia – Evidence of Amyloid Scanning (IDEAS study) was a community-based research study that used PET scans to detect amyloid pathology. A subset of patients in the IDEAS study also received AD blood biomarkers.
In this webinar, the speakers will discuss the real-world use of PET scans and review the concordance of the PrecivityAD2™ blood test with amyloid PET scans and cerebrospinal fluid (CSF) tests.
Register for this webinar today to understand the critical role of blood biomarkers in Alzheimer’s disease diagnosis and management.
Keywords: Alzheimer's, Alzheimer's Disease, Drug Development, Neurodegenerative Disease, Amyloid Beta, Biomarkers, Clinical Data, Diagnostics, Therapeutic Areas, CNS, Laboratory Technology, Bioanalytical Testing